key: cord-0841036-irlyecto
authors: Ching, Lauren L.; Tseng, Alanna C.; Nakano, Eileen; Salomon, Rennsilve C.; Wang, Wei-Kung; Shikuma, Cecilia; Nerurkar, Vivek R.
title: COVID-19 vaccination and booster induced authentic-virus neutralizing antibody response is superior to SARS-CoV-2 natural infection induced response
date: 2022-05-14
journal: J Clin Virol
DOI: 10.1016/j.jcv.2022.105185
sha: 86d39824c2402a900a65de4861695489a87c1595
doc_id: 841036
cord_uid: irlyecto

nan

Understanding of antibody responses to SARS-CoV-2 natural infection (NI) and/or vaccination is constantly evolving, with most researchers reporting waning immune responses between six to eleven months [1] [2] [3] [4] . Studies have previously investigated antibody kinetics following COVID-19 and/or vaccination in various cohorts and at different periods during the pandemic. However, these studies have primarily relied on binding antibody responses, or pseudovirus-based neutralization assays, rather than authentic-virus neutralization assays evaluating functional antibody responses. Here we characterize neutralizing antibody (NAb) responses using authentic-virus plaque reduction neutralization test (PRNT) among individuals with SARS-CoV-2 NI and/or vaccination.

A total of 449 blood samples were collected from 222 human subjects after obtaining informed consent between July 2020 and December 2021 in Honolulu, Hawaii, USA (IRB#2020-00406). An additional 44 de-identified blood samples were collected from individuals with history of SARS-CoV-2 NI (Table 1) .

PRNTs were conducted as previously described using the SARS-CoV-2 isolate USA-WA1/2020 [5] . Sigmoidal-dose-response-logisticregression model was used to determine PRNT titers at 50% neutralization. All calculations were conducted using GraphPad(v9.0).

Functional neutralization assay, expressed as median NAb titers and IQR, revealed significantly lower titers among individuals with history of NI alone (608, IQR:241-1,256) compared to NAb titers among individuals with history of NI after at least one dose of COVID-19 vaccination (5,347, IQR:1,433-12,723; p<0.001) or individuals without history of NI after complete COVID-19 vaccination (1,766, IQR:606-4,219; p<0.001). History of previous SARS-CoV-2 NI provided a moderate increase in NAb titers compared to that among SARS-CoV-2 naive individuals following complete COVID-19 vaccination (p=0.033). NAb titers after two dose COVID-19 vaccination series were significantly higher (3,785, IQR:1,837-6,770; p<0.001) than after one dose (310, IQR:93-588), which was further enhanced following booster dose (16,715, IQR:6,671-33,930; p<0.001) (Fig. 1A) . Longitudinal analysis following SARS-CoV-2 NI revealed that NAb titers declined most dramatically within the first six weeks (851 at two weeks vs. 341 at six weeks) after NI. Longitudinal analysis in COVID-19 vaccinated individuals without history of NI showed the largest decline in NAb titers at three-and six-months following completion of primary vaccination (3,785 at two weeks vs. 627 at three months, p<0.001; 557 at six months, p<0.001), which was restored after booster dose administration (p<0.001) (Fig. 1B) . Similar findings were observed in the longitudinal cohort analysis among individuals for which multiple blood draws were obtained (Fig. 1C ).

Based on functional neutralization assay, we report (i) potent COVID-19 vaccine-induced NAb responses are superior to responses following NI (p<0.001); (ii) NI followed by vaccination has a modest advantage in NAb levels when compared to administration of two-dose vaccine series (p=0.033); (iii) NAb responses decline at three-and sixmonths following the second dose of COVID-19 vaccine (p<0.001); and (iv) NAb responses are restored within two weeks following booster dose of COVID-19 vaccine (p<0.001). SARS-CoV-2 antibody responses characterized in this and other studies are similar to those observed following common cold coronavirus infection, which produces waning antibody responses that results in frequent re-infection [6] . These data paired with morbidity and mortality data associated with the onslaught of new SARS-CoV-2 variants will help guide the administration of future booster vaccination.

Abbreviations: NAb, neutralizing antibodies; NI, naturally infected; PRNT, plaque reduction neutralization test. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. . Intervals for the SARS-CoV-2 naturally infected individuals (left) were as follows: i) ≥ 10 days to 6 weeks (NI, ≥ 2wk), ii) ≥ 6 weeks to 6 months (NI, ≥ 6wk), iii) ≥ 6 months (NI, ≥ 6mo) following symptom onset and/or PCR positivity, and iv) asymptomatic SARS-CoV-2 natural infection (ASx). Intervals for the individuals without a history of SARS-CoV-2 natural infection following COVID-19 vaccination (right) were as follows: v) ≥ 10 and ≤ 42 days following one dose of a COVID-19 vaccine (VX-Do1), vi) ≥10 days to 6 weeks (VX-Do2, ≥ 2wk), vii) ≥ 6 weeks to 3 months (VX-Do2, ≥ 6wk), viii) ≥ 3 months to 6 months (VX-Do2, ≥ 3 mo), ix) ≥ 6 months (VX-Do2, ≥ 6 months) following two doses/complete COVID-19 vaccination; and x) with complete COVID-19 vaccination and ≥10 days following booster dose (VX-Do3), without a history of SARS-CoV-2 infection. (C) Longitudinal cohort analysis among the individuals following COVID-19 vaccination without a history of SARS-CoV-2 infection for which multiple blood draws (n = 64) were obtained (two blood draws/collection points, n = 16; three blood draws, n = 22; four blood draws, n = 8; five blood draws, n = 7; six blood draws, n = 8; seven blood draws, n = 3). Samples were collected at i) baseline, ii) ≥ 10 and ≤ 42 days following one dose of a mRNA COVID-19 vaccine (VX-Do1), iii) ≥10 days to 6 weeks (VX-Do2, ≥ 2wk), iv) ≥ 6 weeks to 3 months (VX-Do2, ≥ 6wk), v) ≥ 3 months to 6 months (VX-Do2, ≥ 3mo), vi) ≥ 6 months (VX-Do2, ≥ 6 months) following two doses/complete COVID-19 vaccination; or vii) after complete COVID-19 vaccination and ≥10 days following booster/ third dose (VX-Do3). Kruskal-Wallis ANOVA test for non-parametric data was used to evaluate group differences. Dotted red line is the limit of detection of the neutralizing antibody titer (PRNT ≥ 20). *p≤0.033, **p≤0.002, ***p<0.001.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection

A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter

Seasonal coronavirus protective immunity is short-lasting

University of Hawaii at Manoa, 651 Ilalo Street

Burns School of Medicine, University of Hawaii at Manoa, 651 Ilalo Street